Pliant Therapeutics (NASDAQ:PLRX) Announces Quarterly Earnings Results, Misses Expectations By $0.02 EPS

Pliant Therapeutics (NASDAQ:PLRX) announced its quarterly earnings results on Thursday. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.02), FiscalAI reports.

Pliant Therapeutics Price Performance

Shares of PLRX traded down $0.04 during mid-day trading on Thursday, reaching $0.74. 525,019 shares of the company’s stock were exchanged, compared to its average volume of 548,164. The business’s fifty day simple moving average is $0.99 and its 200-day simple moving average is $1.14. The stock has a market capitalization of $45.82 million, a PE ratio of -0.50 and a beta of 1.36. Pliant Therapeutics has a 52-week low of $0.73 and a 52-week high of $1.80.

Analysts Set New Price Targets

Several brokerages have issued reports on PLRX. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Pliant Therapeutics in a report on Thursday, October 15th. Wall Street Zen cut Pliant Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 7th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $3.00.

Pliant Therapeutics Company Profile

Pliant Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing therapies for fibrotic diseases. The company’s research is centered on integrin biology, a field involving proteins that regulate cell communication and tissue remodeling. Pliant aims to develop medicines that address the underlying processes that drive fibrosis in organs such as the lungs and liver. Pliant’s lead investigational product is bexotegrast, an oral, selective inhibitor of the integrins ?v?1 and ?v?6.